Evidence map›Paper›PMID 26316159›Full record

ReviewRadiation oncology (London, England)2015

Next-generation sequencing: hype and hope for development of personalized radiation therapy?

Ingeborg Tinhofer, Franziska Niehr, Robert Konschak, Sandra Liebs, Matthias Munz, Albrecht Stenzinger, Wilko Weichert, Ulrich Keilholz, Volker Budach

Abstract readReview
In one paragraph

Review in Radiation oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Recent advances and future of immunotherapy for glioblastoma.Expert opinion on biological therapy · 2016
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ingeborg TinhoferDepartment of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Translational Radiation Oncology Research Laboratory, Charitéplatz 1, 10117, Berlin, Germany. ingeborg.tinhofer@charite.de.
Franziska NiehrDepartment of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Translational Radiation Oncology Research Laboratory, Charitéplatz 1, 10117, Berlin, Germany.
Robert KonschakDepartment of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Translational Radiation Oncology Research Laboratory, Charitéplatz 1, 10117, Berlin, Germany.
Sandra LiebsGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) partner site, Heidelberg, Germany.
Matthias MunzGroup for Computational Modelling in Medicine, Institute for Theoretical Biology, Humboldt Universität, Berlin, Germany.
Albrecht StenzingerInstitute of Pathology, University Hospital and National Center for Tumor Diseases, Heidelberg, Germany.
Wilko WeichertInstitute of Pathology, University Hospital and National Center for Tumor Diseases, Heidelberg, Germany.
Ulrich KeilholzCharité Comprehensive Cancer Center, Charité University Hospital, Berlin, Germany.
Volker BudachDepartment of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Translational Radiation Oncology Research Laboratory, Charitéplatz 1, 10117, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of next-generation sequencing (NGS) in the field of cancer research has boosted worldwide efforts of genome-wide personalized oncology aiming at identifying predictive biomarkers and novel actionable targets. Despite considerable progress in understanding the molecular biology of distinct cancer entities by the use of this revolutionary technology and despite contemporaneous innovations in drug development, translation of NGS findings into improved concepts for cancer treatment remains a challenge. The aim of this article is to describe shortly the NGS platforms for DNA sequencing and in more detail key achievements and unresolved hurdles. A special focus will be given on potential clinical applications of this innovative technique in the field of radiation oncology.

Indexed as

High-Throughput Nucleotide SequencingHumansNeoplasmsPrecision MedicineRadiotherapy

Identifiers

PMID26316159
PMCPMC4554356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.